Shares of Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) traded up 4.7% during mid-day trading on Monday . The company traded as high as $4.09 and last traded at $4.03, with a volume of 316,803 shares. The stock had previously closed at $3.85.

The stock has a 50 day moving average price of $3.53 and a 200 day moving average price of $4.37. The firm’s market capitalization is $250.95 million.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last issued its quarterly earnings data on Tuesday, May 10th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by $0.48. The firm earned $8.10 million during the quarter, compared to analyst estimates of $9.70 million. The company’s quarterly revenue was up 84.1% compared to the same quarter last year. On average, analysts predict that Aralez Pharmaceuticals Inc. will post ($1.00) earnings per share for the current fiscal year.

In other Aralez Pharmaceuticals news, insider Andrew I. Koven bought 71,500 shares of Aralez Pharmaceuticals stock in a transaction that occurred on Thursday, May 12th. The shares were purchased at an average cost of $3.49 per share, for a total transaction of $249,535.00. Following the completion of the transaction, the insider now owns 1,610,306 shares of the company’s stock, valued at approximately $5,619,967.94. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Eric Trachtenberg bought 10,000 shares of Aralez Pharmaceuticals stock in a transaction that occurred on Monday, May 16th. The shares were acquired at an average price of $3.76 per share, for a total transaction of $37,600.00. Following the completion of the transaction, the insider now directly owns 144,500 shares of the company’s stock, valued at approximately $543,320. The disclosure for this purchase can be found here.

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.